Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study.
Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, Yusuf S, Mann JF; ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease). Clase CM, et al. Among authors: grosshennig a. Ann Intern Med. 2011 Mar 1;154(5):310-8. doi: 10.7326/0003-4819-154-5-201103010-00005. Ann Intern Med. 2011. PMID: 21357908
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF; ONTARGET and TRANSCEND Investigators. Tobe SW, et al. Among authors: grosshennig a. Circulation. 2011 Mar 15;123(10):1098-107. doi: 10.1161/CIRCULATIONAHA.110.964171. Epub 2011 Feb 28. Circulation. 2011. PMID: 21357827 Clinical Trial.
The Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial.
Müller-Vahl KR, Pisarenko A, Ringlstetter R, Cimpianu CL, Fremer C, Weidinger E, Jenz EB, Musil R, Brunnauer A, Großhennig A. Müller-Vahl KR, et al. Among authors: grosshennig a. Cannabis Cannabinoid Res. 2024 Oct;9(5):1349-1359. doi: 10.1089/can.2023.0114. Epub 2024 Jan 23. Cannabis Cannabinoid Res. 2024. PMID: 38265476 Clinical Trial.
Simple and safe digitoxin dosing in heart failure based on data from the DIGIT-HF trial.
Bavendiek U, Großhennig A, Schwab J, Berliner D, Liu X, Maier L, Gaspar T, Rieth A, Philipp S, Hambrecht R, Westenfeld R, Münzel T, Winkler S, Hülsmann M, Westermann D, Zdravkovic M, Lichtinghagen R, von der Leyen H, Zimmermann S, Veltmann C, Böhm M, Störk S, Koch A, Bauersachs J. Bavendiek U, et al. Among authors: grosshennig a. Clin Res Cardiol. 2023 Aug;112(8):1096-1107. doi: 10.1007/s00392-023-02199-z. Epub 2023 Apr 22. Clin Res Cardiol. 2023. PMID: 37087503 Free PMC article. Clinical Trial.
Reply to Li and Colleagues.
Kratz CP, Smirnov D, Autry R, Jäger N, Waszak SM, Großhennig A, Berutti R, Wendorff M, Hainaut P, Pfister SM, Prokisch H, Ripperger T, Malkin D. Kratz CP, et al. Among authors: grosshennig a. J Natl Cancer Inst. 2023 Jun 8;115(6):760-761. doi: 10.1093/jnci/djad057. J Natl Cancer Inst. 2023. PMID: 37004196 Free PMC article. No abstract available.
BISCIT: Biliary interventions in critically ill patients with secondary sclerosing cholangitis-a study protocol for a multicenter, randomized, controlled parallel group trial.
Stahl K, Klein F, Voigtländer T, Großhennig A, Book T, Müller T, Wree A, Kuellmer A, Weigt J, Dechene A, Wedi E, Kandulski A, Lange CM, Holzwart D, von Witzendorff D, Ringe KI, Wedemeyer H, Heidrich B; BISCIT Study group. Stahl K, et al. Among authors: grosshennig a. Trials. 2023 Mar 31;24(1):247. doi: 10.1186/s13063-023-07260-w. Trials. 2023. PMID: 37004078 Free PMC article.
82 results